Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: E_K_S who wrote (19803)	10/8/2004 2:08:17 PM
From: Spekulatius	Respond to of 78622

re MRK, PFE, BMY and AMGN - I think your estimate of the low twenties for MRK is not too far off. i also think htey will eventually cut their dividend. BMY - i commented on this on a few times on this thread. While I like their progress in their early R&D pipeline, they will have to paddle pretty ahrd for 20-3 years just to stay where they are revnue wise, due to patent expirations. together with rising R&D costs this will mean flat to falling earnings. In the pharma sector I do like and own PFE and AMGN. AMGN is expensive per P/S but they have a pretty clear sailing ahead of them. I think the stock is undervalued, as is PFE (and maybe WYE depending on litigation).